Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: Amphastar is a bio-pharmaceutical company focused on developing, manufacturing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredients (API). Key products include BAQSIMI® (glucagon nasal powder), Primatene MIST®, and various critical care drugs.
Key Financial Metrics
| Metric (in thousands, except per share) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Net Revenues | $191,214 | $180,556 | $545,444 | $466,290 |
| Gross Profit | $101,941 | $108,403 | $287,207 | $254,981 |
| Gross Margin | 53.3% | 60.0% | 52.7% | 54.7% |
| Net Income | $40,429 | $49,222 | $121,555 | $101,378 |
| Diluted EPS | $0.78 | $0.91 | $2.32 | $1.91 |
| Operating Cash Flow (9M) | $184,362 | $159,639 | N/A | N/A |
| Cash & Equivalents (Sep 30, 2024) | $192,116 | N/A | N/A | N/A |
| Total Debt (Sep 30, 2024) | $609,218 | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 6% in Q3 2024 and 17% in the first nine months of 2024 compared to the prior year. This growth was primarily driven by the inclusion of BAQSIMI® sales, which shifted from a net royalty basis (Other Revenues) to gross product revenue as the company assumed distribution responsibilities from Eli Lilly.
- BAQSIMI® Transition: In Q3 2024, $40.4 million of BAQSIMI® sales were recognized as product revenue, compared to $0 in Q3 2023 (where sales were recognized net). Consequently, "Other Revenues" dropped significantly from $28.7 million in Q3 2023 to $2.4 million in Q3 2024.
- Gross Margin Compression: Gross margins decreased from 60.0% in Q3 2023 to 53.3% in Q3 2024. This decline is attributed to the shift in BAQSIMI® revenue recognition (now including cost of goods sold), increased labor and component costs, and inventory write-downs to net realizable value.
- Operating Expenses: Selling, distribution, and marketing expenses rose 40% in Q3 2024 due to expanded marketing efforts for BAQSIMI®. Research and development expenses increased 26% due to higher raw material costs for the insulin pipeline and personnel expenses.
- Interest Expense: Interest expense decreased 51% in Q3 2024 compared to Q3 2023, largely due to the repayment of a $250 million Wells Fargo Term Loan in September 2023 and the write-off of associated issuance costs in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued revenue growth from higher-margin products like BAQSIMI®, Primatene MIST®, and new launches (e.g., albuterol). However, API sales are expected to remain lower than historical levels for the next two years as a major customer qualifies upgraded insulin API.
- Share Buybacks: The Board authorized a $50 million increase to the share buyback program in June 2024 and another $50 million increase in November 2024. The company purchased $35.0 million of stock in Q3 2024.
- Contingent Consideration: The company may be required to pay up to $575.0 million in contingent cash consideration for the BAQSIMI® acquisition based on net sales milestones. No milestones have been triggered as of September 30, 2024.
- Risks:
- Supply Chain & Natural Disasters: Hurricane Helene caused shipment delays, deferring $2.0–$4.0 million in expected Q3 sales to Q4. The company relies on single-source suppliers for certain raw materials.
- Regulatory: The company received Form 483 observations from FDA inspections at its Rancho Cucamonga and Canton facilities in 2024 but believes responses will satisfy requirements.
- Related Party Pledges: Significant shareholders (Drs. Zhang and Luo) have pledged shares to secure personal loans. A decline in stock price could trigger margin calls or forced sales, potentially impacting the stock price.
- Litigation: The company is defending against employment class actions and a patent infringement lawsuit regarding its albuterol product.
Investor Verification Checklist
- BAQSIMI® Revenue Recognition: Verify the timeline for the full transition of BAQSIMI® distribution from Eli Lilly to Amphastar across all territories to understand the normalization of gross margins.
- API Sales Trajectory: Monitor the qualification status of the upgraded Recombinant Human Insulin (RHI) API with MannKind, as this is a key driver for the API segment's recovery.
- Inventory Valuation: Review future quarters for continued charges related to inventory adjustments to net realizable value, which impacted Q3 margins.
- Debt Obligations: Confirm the status of the $575 million contingent consideration for the BAQSIMI® acquisition and the repayment schedule for the 2029 Convertible Notes ($345 million principal).
- Related Party Exposure: Assess the risk of forced share sales by major shareholders due to pledged collateral if the stock price declines significantly.